Fourth-Generation CAR T Cells Targeting MUC1 Show Enhanced Power Against Breast Cancer

Scientists in Thailand have engineered a next-generation immune cell therapy that appears to outperform conventional designs in laboratory models of breast cancer, one of the deadliest and most treatment-resistant malignancies worldwide. The research, published in Cancer Immunology, Immunotherapy, describes fourth-generation chimeric antigen receptor T cells, known as αM.CAR4, that home in on mucin 1, a protein prominently displayed on breast cancer cells but largely absent from healthy tissues. In a series of head-to-head comparisons with traditional second- and third-generation CAR constructs, the fourth-generation cells proliferated more vigorously, resisted exhaustion more effectively, killed tumor cells at lower doses, and dismantled three-dimensional tumor spheroids faster than their predecessors.

The work addresses one of the most stubborn problems in modern oncology: translating the spectacular success of CAR T cell therapy in blood cancers into solid tumors. Since the first CAR T products received regulatory approval, patients with certain leukemias and lymphomas have benefited from engineered immune cells that can seek out and destroy malignant cells bearing a specific molecular marker. Solid tumors, however, have proven far more difficult targets. They deploy hostile microenvironments, suppressive signaling pathways, and heterogeneous surface antigens that blunt the activity of infused cells. Breast cancer, the leading cause of cancer-related mortality globally, exemplifies these challenges, and the study’s authors frame their work as a direct response to this unmet clinical need.

The choice of target antigen is central to the strategy. Mucin 1 is a large, heavily glycosylated protein that normally lines the apical surfaces of epithelial tissues, where it plays protective roles. In tumor cells, however, glycosylation patterns break down, producing a hypoglycosylated, tumor-associated form of MUC1 that is exposed in ways the normal protein is not. This aberrant presentation makes MUC1 an attractive target for T cell-based therapies, because the abnormal form is largely absent from normal tissues, potentially widening the therapeutic window. The team, led by researchers at the Siriraj Center of Research Excellence for Cancer Immunotherapy at Mahidol University’s Faculty of Medicine Siriraj Hospital, set out to establish both the clinical relevance of MUC1 and the superiority of a fourth-generation receptor design against it.

To establish that relevance, the investigators turned to The Cancer Genome Atlas, a large public repository of genomic and clinical data. Their analysis revealed that high MUC1 expression in breast cancer is associated with reduced overall survival and reduced disease-free survival, positioning MUC1 not merely as a target but as a potential prognostic biomarker that could help identify patients with aggressive disease. The genomic signal was then corroborated at the protein level. Using immunohistochemical staining on patient tissue samples, the researchers found that 57 of 59 breast cancer samples, or 96.6 percent, were positive for MUC1. High MUC1 expression was also confirmed across breast cancer cell lines used in the laboratory experiments, ensuring that the preclinical models faithfully reflected the antigen landscape of human tumors.

With the target validated, the team constructed and compared three CAR designs. Second-generation receptors, the workhorse of approved therapies, combine an antigen-binding domain with a single intracellular costimulatory module, typically CD28 or 4-1BB, fused to the CD3 zeta signaling chain. Third-generation receptors add a second costimulatory domain in an effort to amplify activation. Fourth-generation receptors go further, incorporating an additional genetic payload, often encoding a cytokine or other immune-enhancing factor, that is expressed upon antigen engagement, effectively turning the engineered cell into a localized delivery system for immune stimulation. The αM.CAR4 construct paired an anti-MUC1 single-chain variable fragment, the HMFG2 sequence generously provided by Professor John Maher, with this augmented signaling architecture.

The comparative evaluation began at baseline, where the fourth-generation cells displayed immunophenotypes broadly comparable to those of the second- and third-generation counterparts, indicating that the added complexity had not fundamentally altered the cells’ resting state. The differences emerged dramatically after antigen exposure. When the engineered cells encountered MUC1-expressing tumor cells, the αM.CAR4 T cells demonstrated significantly the highest proliferation among the three designs while simultaneously exhibiting the lowest exhausted phenotype, a statistically significant advantage at the p less than 0.05 threshold. T cell exhaustion, a dysfunctional state marked by inhibitory receptor upregulation and loss of effector function, is a major cause of CAR T failure in solid tumors, making this resilience particularly noteworthy.

Cytotoxic performance told a similar story. The fourth-generation cells required markedly lower doses to achieve higher levels of tumor cell killing, a difference significant at the p less than 0.01 level, suggesting that each αM.CAR4 cell packs greater lethal capacity per encounter. Consistent with this, the cells produced significantly higher levels of cytotoxic effector proteins, the molecular weapons, including granzymes and perforin, that engineered T cells deploy to punch holes in tumor cell membranes and trigger programmed cell death. In three-dimensional spheroid models, which better mimic the dense architecture of real tumors than flat cell cultures, the αM.CAR4 cells induced rapid spheroid destruction, again reaching statistical significance at p less than 0.05. Together, these assays paint a picture of a receptor design that not only survives antigen stimulation but converts it into sustained, potent anti-tumor activity.

The implications extend in two directions. Clinically, the findings support MUC1 expression as a potential prognostic biomarker in breast cancer, offering a molecular handle for risk stratification that could complement existing markers. Therapeutically, the results argue that fourth-generation CAR architecture may be the key to unlocking MUC1-directed immunotherapy for solid tumors, where earlier generations have struggled. Because the tumor-associated form of MUC1 is largely absent from normal tissues, the approach may also carry a favorable safety profile compared with targets shared between healthy and malignant cells, though on-target off-tumor effects against epithelial tissues will require careful evaluation in future studies.

The researchers are careful to position this work as a foundation rather than a finished therapy. Their summary explicitly states that αM.CAR4 T cells represent a promising alternative strategy for breast cancer immunotherapy and that the findings support further development and evaluation of MUC1-targeting CAR T cells in pre-clinical and clinical studies. The road from laboratory bench to approved treatment is long, involving manufacturing optimization, safety pharmacology, dose escalation, and ultimately randomized clinical trials. Yet the convergence of near-universal MUC1 expression in patient samples, a clear survival correlation from genomic data, and demonstrable functional superiority of the fourth-generation design gives the field a coherent rationale for advancing this approach.

The study also reflects a broader international and collaborative effort. The work was conducted by teams spanning Mahidol University’s Siriraj Hospital in Bangkok, including the Division of Head-Neck and Breast Surgery, the Department of Pathology, and the Department of Immunology, in partnership with Kumamoto University in Japan, where co-author Seiji Okada leads the Division of Hematopoiesis at the Joint Research Center for Human Retrovirus Infection. Many of the investigators are members of the Thailand Hub of Talents in Cancer Immunotherapy, supported by the National Research Council of Thailand, with additional funding from Mahidol University and Siriraj Research Fund. As breast cancer continues to claim lives worldwide despite advances in surgery, chemotherapy, and targeted agents, engineered immune cells capable of recognizing the aberrant molecular signature of malignancy, and sustaining their attack where earlier designs falter, offer a compelling glimpse of where cancer immunotherapy may be headed next.

Subject of Research: Development of fourth-generation chimeric antigen receptor T cells targeting mucin 1 for enhanced immunotherapy of breast cancer

Article Title: Fourth-generation chimeric antigen receptor T cells targeting mucin 1 for enhanced anti-tumor activity against breast cancer

Article References: Supimon, K., Sangsuwannukul, T., Sawasdee, N., Choomee, K., Natungnuy, K., Nganrungreung, S., Tripatara, P., Jirawatnotai, S., Sa-nguanraksa, D., Warnnissorn, M., Thuwajit, C., Okada, S., Junking, M., & Yenchitsomanus, P.-T. (2026). Fourth-generation chimeric antigen receptor T cells targeting mucin 1 for enhanced anti-tumor activity against breast cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04557-y

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04557-y

Keywords: breast cancer, CAR T cells, chimeric antigen receptor, mucin 1, cancer immunotherapy, MUC1, fourth-generation CAR, T cell exhaustion, tumor immunology, prognostic biomarker, immunotherapy, solid tumors